Figuring out Mounjaro insurance coverage in Canada is one of the most frustrating parts of getting on tirzepatide. The medication works, the clinical data is strong, and your doctor may have already recommended it. But when you show up at the pharmacy, the sticker shock hits hard. Without coverage, a single Mounjaro pen runs over $800 per month.
I've spent the past several weeks mapping out which provincial plans cover tirzepatide, what private insurers are doing, and exactly how to push a prior authorization through. If you're trying to get Mounjaro covered in Canada in 2026, this is everything you need to know.
Quick summary: Most provincial drug plans do not cover Mounjaro for weight management as of April 2026. Ontario, Quebec, and British Columbia list tirzepatide for type 2 diabetes under restricted criteria only. Private insurance coverage varies widely. Sun Life, Manulife, and Canada Life all have pathways to approval, but prior authorization is almost always required. The myMounjaro savings card can reduce your out-of-pocket cost by 25–40% while you work on getting full coverage.
Why Mounjaro Coverage in Canada Is Complicated
Mounjaro (tirzepatide) sits in a tricky spot. Health Canada approved it, and the Canadian Drug Expert Committee (CDEC) issued a positive recommendation through CADTH. But approvals at the federal review level do not automatically translate into provincial formulary listings or private insurance inclusion. [1]
Each province runs its own drug plan. Each private insurer sets its own policies. And because Mounjaro is newer than Ozempic or Wegovy, many plans haven't caught up yet.
Here is how the coverage landscape breaks down right now.
Provincial Drug Plan Coverage for Mounjaro
Provincial drug plans in Canada cover medications through public formularies. Getting listed on a formulary requires a CADTH recommendation, a price negotiation through the pan-Canadian Pharmaceutical Alliance (pCPA), and then a decision by each individual province.
As of April 2026, Mounjaro has completed the CADTH review process and pCPA negotiations. Provincial listings are rolling out, but slowly and with strict conditions. [2]
Province-by-Province Mounjaro Coverage Table
| Province | Coverage Status | Conditions | Notes |
|----------|----------------|------------|-------|
| Ontario (ODB) | Restricted listing | Type 2 diabetes only; must have tried metformin first | Requires Limited Use code from prescriber |
| Quebec (RAMQ) | Restricted listing | Type 2 diabetes; A1C above 7% despite metformin | Listed as an exception drug; requires prior authorization |
| British Columbia (PharmaCare) | Special Authority | Type 2 diabetes; failure on at least one oral agent | Special Authority form must be completed by physician |
| Alberta | Under review | Not yet listed | Expected decision Q3 2026 |
| Manitoba | Under review | Not yet listed | Following pCPA negotiations |
| Saskatchewan | Under review | Not yet listed | No timeline announced |
| Nova Scotia | Not listed | N/A | Awaiting provincial review |
| New Brunswick | Not listed | N/A | No coverage at this time |
| Newfoundland & Labrador | Not listed | N/A | Under federal review alignment |
| PEI | Not listed | N/A | No formulary listing |
A few things jump out from this table. First, no province covers Mounjaro for weight management alone. Every listing so far is restricted to type 2 diabetes. Second, even in provinces where it is listed, you need to meet specific clinical criteria and usually require prior authorization. [3]
If you are taking Mounjaro specifically for weight loss and do not have a type 2 diabetes diagnosis, provincial drug plans will not help you right now. That makes private insurance or out-of-pocket payment (with the myMounjaro savings card) the only realistic options for many Canadians.
Private Insurance Coverage for Mounjaro in Canada
Private drug plans through employers or individual policies are where most working Canadians actually get their Mounjaro covered. The good news is that several major insurers now include tirzepatide on their formularies. The less good news is that almost all of them require prior authorization (PA), and approval rates depend heavily on how the paperwork is submitted.
Private Insurer Coverage Table
| Insurer | Mounjaro Coverage | PA Required? | Key Requirements |
|---------|-------------------|--------------|------------------|
| Sun Life | Yes (restricted) | Yes | Must have type 2 diabetes or BMI 30+; prescriber letter required |
| Manulife | Yes (restricted) | Yes | Type 2 diabetes or BMI 30+ with comorbidity; step therapy may apply |
| Canada Life (Great-West Life) | Yes (restricted) | Yes | Requires proof of failed weight management program or prior GLP-1 use |
| Desjardins Insurance | Yes (select plans) | Yes | Varies by employer group plan; some plans exclude weight-loss drugs |
| Blue Cross (various provinces) | Partial | Yes | Coverage depends on provincial Blue Cross entity; Alberta Blue Cross more likely to approve |
| Green Shield Canada | Under review | N/A | Not yet broadly covered; case-by-case exceptions possible |
| Equitable Life | Limited | Yes | Coverage available in some group plans; individual plans unlikely |
"Restricted" does not mean automatic coverage. It means the insurer has a pathway to say yes, but you and your doctor have to fill out the right forms and meet specific medical criteria. The process can take two to six weeks. [4]
What Insurers Look For
When a private insurer reviews a Mounjaro prior authorization, they typically want to see:
- A confirmed diagnosis. Type 2 diabetes gets approved most easily. For weight management, you generally need a BMI of 30 or higher, or a BMI of 27+ with at least one weight-related comorbidity (high blood pressure, sleep apnea, prediabetes, etc.).
- Step therapy documentation. Many insurers want evidence that less expensive treatments were tried first. This might mean showing that metformin, a sulfonylurea, or even semaglutide (Ozempic) did not produce adequate results.
- A prescriber letter. A letter from your doctor explaining why Mounjaro is medically necessary for your specific situation. Generic letters get denied. Detailed, patient-specific letters get approved.
- Lab work. Recent A1C results, fasting glucose, lipid panels, and sometimes liver function tests.
For a broader look at the options available to you, see our guide on how to get Mounjaro in Canada.
Mounjaro vs Ozempic: Insurance Coverage Comparison
Many people ask whether it's easier to get Ozempic covered than Mounjaro. Right now, it usually is. Ozempic has been on the market longer, it has more formulary listings, and insurers have more experience processing claims for it. [6]
Coverage Comparison Table: Mounjaro vs Ozempic
| Factor | Mounjaro (Tirzepatide) | Ozempic (Semaglutide) |
|--------|------------------------|------------------------|
| Provincial formulary listings | 3 provinces (restricted) | 10 provinces (most with restrictions) |
| Private insurance coverage | Growing but limited | Widely covered |
| Prior authorization required | Almost always | Often, but not always |
| Approved indication (Canada) | Type 2 diabetes | Type 2 diabetes |
| Weight management indication | Not yet approved separately | Not approved (Wegovy is the weight-loss brand) |
| Step therapy hurdle | High (newer drug) | Lower (established drug) |
| Average monthly cost without insurance | $800+ | $300–$350 |
| Average monthly cost with savings card | $301–$502 | N/A (no comparable savings program) |
Ozempic currently wins on coverage availability, but Mounjaro often wins on clinical outcomes. The SURMOUNT trials showed tirzepatide producing 20–22% average body weight reduction, compared to roughly 15% with semaglutide at the 2.4 mg dose used in Wegovy (Jastreboff et al., New England Journal of Medicine, 2022). [5]
If your insurer denies Mounjaro, they may approve Ozempic first. Some patients use this as a stepping stone: try Ozempic, document that it is insufficient, then reapply for Mounjaro with that evidence. For a detailed comparison, see our Wegovy vs Mounjaro breakdown.
What Mounjaro Costs With and Without Insurance
Cost Comparison: Insured vs Uninsured
| Scenario | Monthly Cost (CAD) | Annual Cost (CAD) | Notes |
|----------|-------------------|-------------------|-------|
| No insurance, no savings card | $800–$1,000+ | $9,600–$12,000+ | Full retail price |
| No insurance, with myMounjaro card | $301–$502 | $3,612–$6,024 | 25–40% discount depending on dose |
| Private insurance (80% coverage) | $60–$100 | $720–$1,200 | After copay; assumes PA approved |
| Private insurance (100% coverage) | $0 | $0 | Rare; some executive plans |
| Provincial plan (if eligible) | $0–$50 | $0–$600 | Copay varies by province; type 2 diabetes only |
| Provincial plan + myMounjaro card | $0 | $0 | Stacking may be possible in some cases |
The difference between paying $12,000 a year and paying $720 is enormous. That's why fighting for coverage and understanding the prior authorization process matters. [7]
For a full cost breakdown by dose, see our Mounjaro cost guide.
Generic Semaglutide at In-Person Canadian Pharmacies
Cash retail prices for generic semaglutide at Canadian pharmacies are now coming in below the telehealth alternatives, based on early Canadian consumer reports. Costco Pharmacy is the lowest reliable option at roughly $88 to $99 per month (confirmed pickups: $88.88 GTA, $88 Ontario, $99 Laval, $91 Medicine Hat). Walmart and Loblaws No Frills typically come in around $95 to $110 per month. Shoppers Drug Mart, Rexall and London Drugs are running roughly $100 to $120 per month (one Halifax-area Shoppers fill reported $113 for the 0.25mg starter dose). Apotex's Apo-Semaglutide Injection began shipping to Canadian pharmacies on May 20, 2026, with Dr. Reddy's generic also launching in May 2026.
That makes in-person pharmacies — especially Costco — meaningfully cheaper than telehealth providers for generic semaglutide. Felix Health and Hims Canada both list $149 per month all-in for the same generic Apo-Semaglutide on their public pricing pages. For most Canadians with a valid prescription, walking it into a local pharmacy is now the cheapest reliable path.
Pricing context: per the Globe and Mail, Apotex's published wholesale price is $78.14 for a four-week supply — roughly one-third of brand-name Ozempic's $240.48 wholesale price. Retail estimates above reflect that wholesale plus each chain's standard dispensing fee and markup. See also coverage from CBC News on the Canadian launch. Note: This generic launch is for semaglutide (Ozempic-equivalent), not tirzepatide. Generic Mounjaro is still years away — Eli Lilly's patents on tirzepatide extend through 2036+. Under the pan-Canadian Pharmaceutical Alliance framework, the maximum public drug plan price for generic semaglutide is approximately $114 per four-week supply with two manufacturers approved, dropping to roughly $80 once a third manufacturer launches.
How to Get Prior Authorization for Mounjaro: Step by Step
Most Mounjaro coverage denials happen because the PA form was incomplete, the clinical rationale was weak, or required documentation was missing.
Prior Authorization Steps
| Step | Action | Who Does It | Timeline |
|------|--------|-------------|----------|
| 1 | Confirm your plan covers Mounjaro | You (call insurer or check formulary) | Day 1 |
| 2 | Book an appointment with your prescriber | You | Day 1–7 |
| 3 | Get required lab work done | You (at lab) | Day 7–14 |
| 4 | Prescriber completes PA form and writes medical necessity letter | Your doctor | Day 14–21 |
| 5 | Submit PA to insurer (fax or online portal) | Doctor's office or pharmacy | Day 21–23 |
| 6 | Insurer reviews and requests any missing info | Insurer | Day 23–35 |
| 7 | Receive approval or denial letter | Insurer sends to you and prescriber | Day 35–42 |
| 8 | If denied, file an appeal with additional documentation | You and your doctor | Day 42–60 |
Tips:
- Call your insurance company first and ask: “Is tirzepatide (Mounjaro) on our formulary, and what does the prior authorization require?” Get the exact PA form they use.
- Make your doctor's letter specific to you, including diagnoses, weight history, previous treatments, and why tirzepatide is appropriate.
- Submit all documentation at once (PA form, labs, letter, chart notes if needed) to avoid delays.
Common Denial Reasons and How to Fight Back
About 30–40% of initial Mounjaro PAs get denied, but many are overturned on appeal.
Denial Reasons and Solutions Table
| Denial Reason | What It Means | How to Respond |
|---------------|---------------|----------------|
| "Not on formulary" | Your specific plan doesn't list Mounjaro | Request an exception review; provide clinical evidence for medical necessity |
| "Step therapy not completed" | Insurer wants you to try cheaper drugs first | Have your doctor document why alternatives are inappropriate or have failed |
| "Insufficient clinical documentation" | PA form was incomplete | Resubmit with full lab work, diagnosis codes, and detailed prescriber letter |
| "Indication not covered" | Your diagnosis (e.g., obesity alone) isn't covered | Ask your doctor to document all comorbidities; some plans only cover for diabetes |
| "Dosage exceeds plan limits" | Insurer only covers lower doses | Prescriber can justify dose titration per product monograph |
| "Prior authorization expired" | PA approval has a time limit (often 6–12 months) | Resubmit renewal PA before expiry date |
An appeal should include:
- A revised prescriber letter addressing the exact denial reason
Online Providers Cost Comparison
Most Canadians now access Mounjaro through telehealth providers rather than in-person clinics. Below is how the main Canadian online providers compare for Mounjaro (tirzepatide) prescribing, with MyRocky now our highest-rated GLP-1 provider overall.
| Provider | Mounjaro Monthly Cost | Consultation Fee | Coverage | Learn More |
|---|---|---|---|---|
| MyRocky | $290 to $440 by dose (2.5 mg to 10 mg pen) | $99 one-time (includes lab work and first prescription) | All 10 provinces (including QC and NB) | Visit MyRocky |
| Felix Health | $800 to $1,000 (savings card may apply) | Free (first), $40 follow-up | All provinces except QC and NB | Visit Felix |
| Maple | $800 to $1,000 (savings card may apply) | $69 one-time | All provinces + territories | Visit Maple |
| Hims Canada | Generic semaglutide available — pricing on consult | Included in plan | ON, BC, AB (expanding 2026) | Visit Hims |
| Raven | Pricing on assessment | Pricing on assessment | 9 provinces | Visit Raven |
MyRocky is our highest-rated Canadian GLP-1 telehealth provider in 2026 (9.4/10). MyRocky ships Health Canada-approved Mounjaro to all 10 provinces (including Quebec and New Brunswick where Felix and Hims do not operate), operates its own LegitScript-certified pharmacy in Mississauga, and employs Canadian-licensed MDs, nurse practitioners and pharmacists. The $99 one-time consultation includes lab work and the first prescription. Read our full MyRocky review.
Sources
- Mounjaro (tirzepatide) Product Information — Eli Lilly Canada — Manufacturer product information for Mounjaro in Canada, including Health Canada–approved indication for type 2 diabetes and prescribing details referenced by formularies and insurers.
- Reimbursement Review: Tirzepatide (Mounjaro) — Canada's Drug Agency (CDA-AMC, formerly CADTH) — Federal reimbursement review and CDEC recommendation for tirzepatide that informs provincial formulary listing decisions.
- Drug Product Database — Health Canada — Official Health Canada database of authorized drug products; confirms Mounjaro's authorized indication for type 2 diabetes in Canada and is the source most public formularies reference for listing decisions.
- BC PharmaCare Publications and Special Authority — British Columbia Ministry of Health — Special Authority criteria, request forms, and adjudication timelines used by BC PharmaCare for tirzepatide and other GLP-1 medications.
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — Jastreboff et al., New England Journal of Medicine, July 2022 — Phase 3 randomized trial showing 20–22% mean body weight reduction with tirzepatide versus placebo, the primary clinical evidence cited in Mounjaro coverage decisions.
- pan-Canadian Pharmaceutical Alliance (pCPA) — Council of the Federation Secretariat — Joint federal–provincial–territorial drug price negotiation body whose completed negotiations on tirzepatide gate provincial formulary listings.
- Ontario Drug Benefit Program and Exceptional Access Program (EAP) — Government of Ontario — Ontario Drug Benefit eligibility, Limited Use codes, and Exceptional Access Program (EAP) process applied to Mounjaro for type 2 diabetes.